Article Text

Download PDFPDF

891 Beta-adrenergic blockade licenses the use of immunotherapy in primary and metastatic brain tumors
  1. Selena J Lorrey1,
  2. Lucas P Wachsmuth1,
  3. Jessica Waibl Polania1,
  4. Alexandra Hoyt-Miggelbrink1,
  5. John Finlay1,
  6. Mackenzie Price1,
  7. Corey Neff1,
  8. Xiuyu Cui1,
  9. Emily Lerner1,
  10. Daniel Wilkinson1,
  11. Kelly Hotchkiss1,
  12. Ethan Srinivasan2,
  13. Quinn T Ostrom1 and
  14. Peter E Fecci3
  1. 1Duke University, Durham, NC, USA
  2. 2Johns Hopkins University, Baltimore, MD, USA
  3. 3Duke Cancer Institute, Durham, NC, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Immunotherapy is less effective against intracranial metastases compared to extracranial metastases and ineffective against primary brain tumors such as glioblastoma. Brain tumors present a unique challenge to in the context of immunotherapy, as these patients are immunosuppressed not just locally at the tumor, but also outside the CNS. Importantly, systemic immunosuppression observed in brain tumor patients limits the capacity of the immune system to respond to immunotherapy.

Methods Preclinical murine models of glioma and brain metastasis were used to uncover the immunologic mechanisms underlying success to immunotherapy in these cancers. Using the SEER Medicaid database, we retrospectively examined outcomes in patients with melanoma and lung adenocarcinoma brain metastasis who received checkpoint blockade therapy alone vs those concurrently on beta-blocker therapy.

Results Through this work we present a novel axis of immunosuppression in patients with intracranial tumors and demonstrate that overactive adrenergic signaling is a major barrier to immunotherapeutic success. Our data indicate that combining beta-adrenergic blockade with immunotherapy provides a survival benefit in the setting of brain tumors, where immunotherapy alone has proven ineffective. We demonstrate that this survival benefit is driven by a remodeling of the tumor microenvironment with an increase in cDC1s and CD8+ T cells, as well as an increase in CD40-CD40L signaling, suggesting the immune system is poised to respond. Further, we demonstrate that beta-adrenergic blockade can overcome systemic immunosuppression to restore the capacity of T cells to respond to an immune stimulus. Further, using the SEER-Medicaid database, we retrospectively examined outcomes in patients with melanoma and lung adenocarcinoma brain metastasis who received checkpoint blockade therapy alone vs those concurrently receiving beta-blocker therapy. We found that patients receiving combination therapy showed increased overall survival compared to those receiving checkpoint blockade alone. We then validated these findings in preclinical models of glioma, demonstrating that combining immunotherapy and propranolol, a widely-prescribed FDA-approved beta-blocker, extended survival.

Conclusions Beta-blockers represent a promising translational intervention that could be readily implemented to license the use of immunotherapy, particularly checkpoint blockade, in patients with primary or metastatic intracranial malignancies.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.